NetworkNewsBreaks

WednesdayMar 17, 2021 10:31 am

NetworkNewsBreaks – MRVL Pet Pharmaceuticals(TM) Corp. to Collaborate with Altran for FDA Clinical Trials on Canine and Feline Cancer and Arthritis Treatment Products

MRVL Pet Pharmaceuticals(TM), a life sciences and technology company focused on the animal health sector, today announced its entry into an agreement with the Life Sciences division of Altran, a Capgemini company, to provide advisory services on their U.S. FDA clinical trial process for canine and feline cancer and arthritis products. According to the update, renowned veterinary expert Dr. Albert Ahn was appointed as the chief researcher of the clinical trial that launched on Jan. 27, 2021, and is expected to consist of three phases and run until Dec. 30, 2022. Altran’s AVP of Regulatory Affairs, Quality and Compliance, Deborah…

Continue Reading

WednesdayMar 17, 2021 10:23 am

NetworkNewsBreaks – Knightscope Inc. Announces Another Crime-Fighting Win

Knightscope, a developer of advanced physical security technologies utilizing fully autonomous security robots (“ASRs”), today provided an update on another crime-fighting win to add to its long list of successes (see www.Knightscope.com/Crime for others). An article published by the Las Vegas Review-Journal discusses the Knightscope MIN31KS, the human-sized autonomous robot that patrols a Las Vegas apartment complex, offering a wide variety of security measures. These include four-camera video recording, facial recognition, license plate reading, verbal warnings, a telephone-like connection with human security officers, as well as a presence that helps deter improper activity. “It’s been very useful in several ways,”…

Continue Reading

WednesdayMar 17, 2021 10:09 am

NetworkNewsBreaks – InnerScope Hearing Technologies Inc. (INND) Announces Official Launch of hearIQ App

InnerScope Hearing Technologies (OTC: INND) today officially announced the launch of its hearIQ App in 172 countries in the Apple App Store for iOS devices and Google Play Store for Android devices. The hearIQ App is a multi-functional solution, which offers to the general public a FREE self-administered hearing test to determine hearing loss (if any) and also provides a Bluetooth wireless connection for InnerScope's direct-to-consumer self-fitting-self-adjusting hearing aids. The hearIQ App is specifically designed to help with early detection of hearing loss for the 48+ million Americans as well as the 1.5 billion people worldwide who, according to the…

Continue Reading

WednesdayMar 17, 2021 10:07 am

NetworkNewsBreaks – Torchlight Energy Resources Inc. (NASDAQ: TRCH) Secures $27M in Underwritten Public Offering

Torchlight Energy (NASDAQ: TRCH), an oil and gas exploration company, has closed an underwritten public offering of 23,000,000 shares of its common stock, including an additional 3,000,000 shares pursuant to the full exercise of the over-allotment option granted to the underwriters. Torchlight Energy secured approximately $27.6 million in gross proceeds, with each of the shares sold at the public offering price of $1.20. The company intends to use the proceeds for general business purposes and to provide $5 million of additional bridge financing to Metamaterial Inc. in connection with the previously announced agreement under which the companies will complete a…

Continue Reading

WednesdayMar 17, 2021 9:50 am

NetworkNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Announces Subsidiary Has Ordered First Shipment of Functional Mushrooms

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) subsidiary Pure Mushrooms Corp. has placed its first order for functional mushrooms from a British Columbia co-packer. Pure Mushrooms will use the mushrooms to produce three products, which will be offered through the company’s online e-commerce store. Previously Pure Mushrooms had developed three premium formulations based on reishi, maitake and lion’s mane mushrooms. These formulations, which are delivered in convenient vegan capsules, will be the foundation of the upcoming new products. Rreishi and maitake formulations should go on sale in April, with the  lion’s mane release slated for June. The announcement…

Continue Reading

WednesdayMar 17, 2021 9:33 am

NetworkNewsBreaks – Brain Scientific Inc. (BRSF) Enters Strategic Collaboration with JelikaLite

Brain Scientific (OTCQB: BRSF), a neurology focused medical device and software company, recently announced a collaboration with JelikaLite, a company developing Cognilum(TM), a non-invasive wearable photobiomodulation device that is being developed to increase the well-being of children living with autism, through a clinical trial. In the trial, “Transcranial Photobiomodulation for Reducing Autism Symptoms in Children,” brain treatments for children diagnosed with autism would be delivered through Cognilum, while Brain Scientific’s NeuroEEG, a wireless EEG device, will monitor brain activity. The trial is designed to provide researchers and clinicians an opportunity to potentially uncover new treatment options for reducing the symptoms…

Continue Reading

TuesdayMar 16, 2021 3:24 pm

NetworkNewsBreaks – Green Hygienics Holdings Inc. (GRYN) Announces Closing of Castillo Assets Acquisition

Green Hygienics Holdings (OTCQB: GRYN) today announced that it has closed the acquisition of certain assets of Castillo Seed LLC. (“Castillo”), a pioneering hemp seed company with an extensive library of proven genetics backed by years of research and development efforts. According to the update, the assets include seed inventories, thousands of stock plants, an established genetics portfolio, and greenhouse and seed production equipment. “We saw an opportunity to fast-track our genetics program by procuring a developed genetics portfolio, which will not only save 3-5 years of R&D work but also allow the company to propagate proprietary USDA Certified Organic…

Continue Reading

TuesdayMar 16, 2021 2:41 pm

NetworkNewsBreaks – Kaival Brands Innovations Group Inc. (KAVL) Releases Q1 Revenue, Gross Profit Numbers

Kaival Brands (OTCQB: KAVL), a company focused on generating shareholder value by incubating innovative products into mature and dominant brands within their respective markets, has reported its Q1 numbers for the period ending Jan. 31, 2021; the report notes first-quarter revenues of $37 million and gross profit totals of $4.8 million. In addition, the company announced that it had achieved cumulative revenue of $100 million in less than a year and has reconfirmed its FY2021 revenue guidance of $400 to $450 million. These revenue milestones were the best to date for Kaival Brands, which is the exclusive global distributor of…

Continue Reading

TuesdayMar 16, 2021 1:52 pm

NetworkNewsBreaks – InsuraGuest Technologies Inc. (TSX.V: ISGI) (OTCQB: ISGIF) Unveils New Limited-Service Hospitality Liability Product

InsuraGuest Technologies (TSX.V: ISGI) (OTCQB: ISGIF), a leading U.S. insurance brokerage and consulting firm, has announced a new product: Limited-Service Hospitality Liability coverages. The product is offered through ISGI’s wholly owned U.S. subsidiary InsuraGuest RPG (“RPG”). The new product will be available to qualifying hotels, which are franchise limited-service hotels with less than 100 rooms and an average daily rate (“ADR”) under $100 a night. Of the 55,900-plus hotel properties in the United States, 33,000 are limited-service hotels, so the intended audience for the new service is impressive. ISGI’s property management system currently integrates with 82 different property management systems through…

Continue Reading

TuesdayMar 16, 2021 1:39 pm

NetworkNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Completes Enrollment in Upcoming Phase 2b Clinical Trial of Cystic Fibrosis Treatment

AzurRx BioPharma (NASDAQ: AZRX), a clinical-stage biopharmaceutical company specializing in the development of targeted, nonsystemic therapies for gastrointestinal (“GI”) diseases, has announced the completion of enrollment for its phase 2b OPTION 2 clinical trial to investigate MS1819 in cystic fibrosis (“CF”) patients with exocrine pancreatic insufficiency (“EPI”). According to the announcement, the company enrolled 30 CF patients for the study, which is anticipated to return top line data by the end of Q1 2021. The upcoming phase 2b, multicenter study will investigate the safety, tolerability and efficacy of MS1819 in a head-to-head comparison against the current porcine enzyme replacement therapy…

Continue Reading